WhaleCreep

Which hedge funds own RARXEUR? RA PHARMACEUTICALS INC, Q2 2026 13F holders

0 tracked hedge funds disclosed a position in RARXEUR (RA PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $0 in total.

0
Holders
0
New this quarter
0
Exited this quarter
$0
Combined value
–
Share of managers holding

Holders, Q2 2026

0 rows

Ownership over time

By quarter
QuarterHoldersManagers filingShare holdingCombined value
Q2 20200680.0%$0
Q1 20205687.4%$377m
Q4 20194676.0%$309m
Q3 20192603.3%$124m
Q2 20192603.3%$155m
Q1 20193605.0%$120m
Q4 20183605.0%$38.5m
Q3 20183595.1%$73.7m
Q2 20182593.4%$39.0m
Q1 20182593.4%$21.4m
Q4 20172593.4%$12.3m
Q3 20171561.8%$19.7m
Q2 20171561.8%$25.3m
Q1 20171561.8%$28.8m
Q4 20161561.8%$20.5m

Who discovered RARXEUR first?

Earliest meaningful positions among the 6 tracked managers seen opening RARXEUR since Q4 2016.

2 rows
RA Capital Management, L.P. high convictionQ4 20162.9%7.4%14Exited by Q2 2020+216%
Pentwater Capital Management LPQ4 20190.3%1.3%2Exited by Q2 2020+2.3%

Stock since is the split-adjusted change in the quarter-end price, excluding dividends, from the first reported quarter: the price the 13F filings themselves imply (value ÷ shares), blank across any gap that cannot be accounted for. It describes the stock, not the return any manager earned.